GlassScriptPhysician profile
Bipin Saud
NPI 1346288958
$5,726.86
in general payments reported to CMS, 2019-2025
32 companies · $525 in 2025
The $525 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $994 · 2021: $943 · 2022: $625 · 2023: $1,115 · 2024: $947 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.55 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,792.90 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $817.46 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $336.64 | 2019-2025 | Xifaxan, Plenvu |
| Qol Medical, LLC | $318.89 | 2019-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $313.85 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $289.86 | 2023-2024 | Zeposia |
| Pfizer INC. | $260.86 | 2023-2025 | |
| Gilead Sciences, INC. | $223.92 | 2019-2024 | |
| Novo Nordisk INC | $160.29 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $135.73 | 2021-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $108.66 | 2021-2022 | |
| Lucid Diagnostics INC. | $80.27 | 2021-2023 | |
| Ambu INC. | $77.22 | 2020 | |
| Redhill Biopharma INC. | $76.14 | 2020-2024 | Talicia |
| Genzyme Corporation | $74.95 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $72.07 | 2023-2024 | Dupixent |
| Braintree Laboratories, INC. | $62.11 | 2019-2024 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $60.63 | 2019-2023 | Ocaliva |
| Astellas Pharma US INC | $51.11 | 2019 | |
| Organon LLC | $45.81 | 2023-2024 | Hadlima |
| Shionogi INC | $45.25 | 2019-2020 | |
| Intra-Sana Laboratories | $41.65 | 2021 | |
| Boston Scientific Corporation | $40.62 | 2020-2025 | Watchman Flx |
| Aimmune Therapeutics, INC. | $40.09 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $33.83 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $33.37 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $28.34 | 2020-2023 | Linzess |
| Ardelyx, INC. | $26.87 | 2022 | |
| Lilly USA, LLC | $25.42 | 2025 | Omvoh |
| Pharmacosmos Therapeutics INC. | $20.01 | 2022 | |
| Cook Medical LLC | $18.76 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipin Saud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.